Initial Response to Treatment was Highly Associated with the Prognosis of Childhood Rhabdomyosarcoma: A Retrospective Analysis of a Single Center Experience in Korea
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Following the introduction of a multimodal approach to diagnosis and treatment, the prognosis of rhabdomyosarcoma (RMS) has markedly improved over the last three decades. However, there are few data on treatment outcomes in Korean patients. Materials and Methods: We performed a retrospective analysis of 77 patients with RMS diagnosed and treated at Seoul National University Children's Hospital between 1986 and 2005. Results: The overall 5-year survival and event-free survival rates for all patients were 77% and 59%, respectively. The Intergroup Rhabdomyosarcoma Study clinical grouping and initial response to treatment (20-week response) were important prognostic factors. Conclusions: The outcome of childhood RMS was closely associated with the initial staging and the initial response to treatment. Modulating therapies according to initial responses and risk factors is critical, and new treatment strategies for high-risk patients are needed.
Abstract
Purpose: Following the introduction of a multimodal approach to diagnosis and treatment, the prognosis of rhabdomyosarcoma (RMS) has markedly improved over the last three decades. However, there are few data on treatment outcomes in Korean patients. Materials and Methods: We performed a retrospective analysis of 77 patients with RMS diagnosed and treated at Seoul National University Children's Hospital between 1986 and 2005. Results: The overall 5-year survival and event-free survival rates for all patients were 77% and 59%, respectively. The Intergroup Rhabdomyosarcoma Study clinical grouping and initial response to treatment (20-week response) were important prognostic factors. Conclusions: The outcome of childhood RMS was closely associated with the initial staging and the initial response to treatment. Modulating therapies according to initial responses and risk factors is critical, and new treatment strategies for high-risk patients are needed.
참고문헌 (22)
- Crist WM, "Common solid tumors of childhood", N Engl J Med, 324, pp.461~71 (1991)
- La Quaglia MP, "The effect of age at diagnosis on outcome in rhabdomyosarcoma", Cancer, 73, pp.109~17 (1994)
- Joshi D., "Age is an independent prognostic factor in rhabdomyosarcoma; A report from the soft tissue sarcoma committee of the children's oncology group", Pediatr Blood Cancer, 42, pp.64~73 (2004)
- Kim JM, "An immunohistochemical study on differential diagnosis of small round cell tumor", J Korean Cancer Assoc, 22, pp.48~61 (1990)
- Maurer HM, "The Intergroup Rhabdomyosarcoma Study-I", Cancer, 61, pp.209~20 (1988)
- Crist W, "The Third Intergroup Rhabdomyosarcoma Study", J Clin Oncol, 13, pp.610~30 (1995)
- Kung FH, "Ifosfamide", carboplatin, II study, pp.J Pediatr Hematol Oncol, 1995[DOI]
- Kaplan E., "Nonparametric estimation from incomplete observation", J Am Stat Assoc, 53, pp.457~81 (1958)
- Peto R., "Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples", Br J Cancer, 35, pp.1~39 (1977)
- Cox DR, "Regression models and life tables", J R Stat Soc, 34, pp.187~220 (1972)
- Koscielniak E., "Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86", J Clin Oncol, 17, pp.3706~19 (1999)
- Wharam MD, "Failure pattern and factors predictive of local failure in rhabdomyosarcoma: a report of group III patients on the third Intergroup Rhabdomyosarcoma Study", J Clin Oncol, 22, pp.1902~8 (2004)
- Punyko JA, "Long-term survival probabilities for childhood rhabdomyosarcoma. A population-based evaluation", Cancer, 103, pp.1475~83 (2005)
- Kim YJ, "Improved treatment result of childhood rhabdomyosarcoma: a single institutional study", Korean J Pediatr Hematol-Oncol, 8, pp.58~66 (2001)
- Burke M., "Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study- IV experience-a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group", J Clin Oncol, 25, pp.4909~13 (2007)
- Blay JY, "High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults", J Clin Oncol, 18, pp.3643~50 (2000)
- Carli M., "High-dose melphalan with autologous stemcell rescue in metastatic rhabdomyosarcoma", J Clin Oncol, 17, pp.2796~803 (1999)
- Lafay-Cousin L., "High-dose thiotepa and hematopoietic stem cell transplantation in pediatric malignant mesenchymal tumors: a phase II study", Bone Marrow Transplant, 26, pp.627~32 (2000)
- Koscielniak E., "Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German", Austrian Pediatric Bone Marrow Transplantation Group, 1997, pp.19, 227~31
- Carli M., "European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors", J Clin Oncol, 22, pp.4787~94 (2004)
- Petak I., "A caspase-8-independent component in TRAIL", Apo-2L-induced cell death in human rhabdomyosarcoma cells, 2003, pp.10, 729~39
- Bersani F., "Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma", Eur J Cancer, 44, pp.876~84 (2008)